Skip to main content
TipRanks
Go Ultimate75% OFF

Kusurinomadoguchi, Inc. (5592) AI Stock Analysis

0 Followers
JP:5592

Kusurinomadoguchi, Inc.

(TSE/TYO:5592)

Select Model
Rating:70Outperform
Price Target:JPY 2,312.00â–²(10.41% Upside)
Action:reiterated
Date:11/18/26

The company's excellent financial performance, marked by high growth and profitability, is the primary strength. A very low P/E ratio further enhances the investment case. However, the technical picture is decisively bearish, with the stock in a clear downtrend, which significantly weighs on the overall score.

Positive Factors
Revenue and profit growthThe multi-year expansion in revenue and net income indicates that the platform is scaling while converting greater activity into earnings. Continued top-line and profit growth can strengthen reinvestment capacity, support product development, and improve the company’s competitive position over the next several quarters.
Negative Factors
Balance-sheet volatilityLarge changes in debt and total assets make the company’s financial structure less predictable and complicate assessment of sustainable leverage. Such volatility can reduce capital-allocation flexibility, increase sensitivity to business fluctuations, and make future funding needs harder to plan with confidence.

Kusurinomadoguchi, Inc. (5592) vs. iShares MSCI Japan ETF (EWJ)

-30%-20%-10%0%10%20%30%JP:5592-21.19%EWJ+11.78%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 21.96B
Dividend Yield
1.81%
Average Volume (3M)
53.03K
Price to Earnings (P/E)
7.9
Beta (1Y)
0.88
Revenue Growth
18.66%
EPS Growth
-10.20%
Country
Japan
Employees
491
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Kusurinomadoguchi, Inc. Business Overview & Revenue Model

Company Description

Kusurinomadoguchi, Inc., established in 2004 and headquartered in Tokyo, Japan, develops and implements a diverse array of technology solutions specifically designed for pharmacies and the wider medical care sector throughout the country. Its compreh...

Kusurinomadoguchi, Inc. Financial Statement Overview

Summary

Strong revenue growth (14% CAGR) and expanding margins (net margin 24% in 2026) are offset slightly by a 2025 cash flow anomaly. The balance sheet is robust with low leverage (D/E 0.25) and high ROE (26%). Overall financial health is excellent.

Income Statement

88Very Positive

Balance Sheet

85Very Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue13.06B12.33B11.20B8.72B7.42B6.49B
Gross Profit7.38B6.97B6.48B4.93B4.07B3.37B
EBITDA4.38B4.19B2.97B2.35B1.68B1.51B
Net Income3.19B2.95B2.03B870.92M391.45M515.61M
Balance Sheet
Total Assets18.23B17.82B12.16B23.07B12.22B11.02B
Cash, Cash Equivalents and Short-Term Investments4.51B5.20B2.15B14.59B5.95B5.02B
Total Debt2.88B2.82B72.47M5.42B137.49M149.56M
Total Liabilities6.77B6.35B3.64B16.65B9.43B8.06B
Stockholders Equity11.35B11.35B8.45B6.37B2.70B2.45B
Cash Flow
Free Cash Flow02.93B-5.37B999.21M1.57B2.58B
Operating Cash Flow02.95B-5.33B2.63B3.10B3.66B
Investing Cash Flow0-2.30B-1.80B-1.79B-1.54B-541.10M
Financing Cash Flow02.22B-5.36B7.81B-635.39M-564.83M

Kusurinomadoguchi, Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price2094.00

Price Trends

50DMA2424.72Negative
100DMA2450.39Negative
200DMA2548.80Negative

Market Momentum

MACD-99.97Negative
RSI34.51Neutral
STOCH45.02Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:5592, the sentiment is Negative. The current price of 2094.00 is below the 20-day moving average (MA) of 2181.00, below the 50-day MA of 2424.72, and below the 200-day MA of 2548.80, indicating a bearish trend. The MACD of -99.97 indicates Negative momentum. The RSI at 34.51 is Neutral, neither overbought nor oversold. The STOCH value of 45.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:5592.

Kusurinomadoguchi, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:5592 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4483JP:448372OutperformJPY 232.67B31.20―0.51%20.50%19.27%
JP:5592JP:559270OutperformJPY 24.00B7.91―1.81%18.66%-10.20%
JP:4480JP:448054NeutralJPY 56.52B32.9911.30%―21.01%10.15%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4438JP:443847NeutralJPY 2.16B-4.71――34.13%35.54%
JP:4263JP:426345NeutralJPY 4.05B-8.15――42.52%-81.61%

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%25%JP:5592JP:4480JP:4263JP:4438JP:4483Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:5592 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:5592Kusurinomadoguchi, Inc.2094.00-562.86-21.19%
JP:4480Medley, Inc.1777.00-873.00-32.94%
JP:4263SUSMED,Inc.239.00-678.00-73.94%
JP:4438Welby Inc.253.00-51.00-16.78%
JP:4483JMDC Inc.3555.00-644.57-15.35%

Kusurinomadoguchi, Inc. Corporate Events

Kusurinomadoguchi Reports Six-Month Results

Nov 17, 2026

Kusurinomadoguchi, Inc. reported revenue of ¥7.236 billion for the six months ended September 30, 2026, up 24.2% year over year, while operating profit rose 19.9% to ¥1.513 billion. Ordinary profit increased 20.3% to ¥1.506 billion, whereas net incom...

Kusurinomadoguchi Material Covers Q2 FY3/2027 Financial Results

Nov 17, 2026

Kusurinomadoguchi, Inc., identified by securities code 5592, is the company named in the supplied material; the text does not provide its industry, primary products or services, or market focus. The document is financial results briefing material for...

Kusurinomadoguchi Maps Out Q1 Results and Multi‑Year Healthcare Tech Strategy

Aug 18, 2026

Kusurinomadoguchi, Inc. reported its financial results for the first quarter of the fiscal year ending March 2027, outlining performance across its main healthcare technology segments. The briefing indicates that management is using this reporting pe...

Kusurinomadoguchi Delivers Strong Q1 as New Acquisitions Lift Earnings

Aug 18, 2026

Kusurinomadoguchi reported robust Q1 FY2027 consolidated results, with revenue rising 25.0% year on year to ¥3,643 million and net income attributable to owners of the parent surging 61.0% to ¥623 million. Earnings per share climbed to ¥54.43, while...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026